NCT03164772View on ClinicalTrials.gov

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

December 20, 2017

Primary Completion Date

October 29, 2021

Study Completion Date

October 29, 2021

Conditions
Metastatic Non-small Cell Lung CancerNSCLC
Interventions
DRUG

Durvalumab

anti-PD-L1

DRUG

Tremelimumab

anti-CTLA-4

BIOLOGICAL

BI 1361849

mRNA Vaccine

DEVICE

PharmaJet Tropis® device

The PharmaJet Tropis® device was used for the intradermal administration of the BI 1361849 vaccine components.

Trial Locations (5)

10016

Research Facility, New York

33612

Research Facility, Tampa

48201

Research Facility, Detroit

53226

Research Facility, Milwaukee

85234

Research Facility, Gilbert

Sponsors
All Listed Sponsors
collaborator

Cancer Research Institute, New York City

OTHER

collaborator

Boehringer Ingelheim

INDUSTRY

collaborator

MedImmune LLC

INDUSTRY

collaborator

CureVac

INDUSTRY

collaborator

PharmaJet, Inc.

INDUSTRY

lead

Ludwig Institute for Cancer Research

OTHER